Second Parathyroid Hormone (PTH) Peptide Drug Patent Awarded to Aegis Therapeutics for Compositions Suitable for Metered Nasal Spray, Oral, and Injectable Delivery
(firmenpresse) - SAN DIEGO, CA -- (Marketwire) -- 05/16/12 -- Aegis Therapeutics LLC announced today that it has been awarded a second patent, U.S. Patent, No. 8,173,594, providing PTH and PTH analog compositions having increased stability and reduced aggregation and aggregation-associated immunogenicity. The stabilized formulations of parathyroid hormone (PTH) and PTH peptide analogs incorporate Aegis' Intravail®/ProTek® excipients suitable for all routes of administration including the non-invasive metered nasal spray delivery route or injection. Intravail® and ProTek® excipients allow for non-invasive delivery with high efficiency and stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants currently found in many protein injectable drugs.
This patent, along with US Patent 8,076,290, has been exclusively licensed to Azelon Pharmaceuticals. All currently approved PTH drug formulations require daily injection. In contrast, Azelon has reported clinical results demonstrating that formulations of teriparatide based upon Aegis' Intravail®/ProTek® show excellent nasal bioavailability offering the prospect of a "first in class" non-injectable PTH drug. Non-injectable dosage forms of previously injectable-only drugs provide greater patient convenience and acceptance, improved compliance, and avoidance of needle-stick injury and disposal problems associated with the use of needles, paving the way to increased market share and substantial growth in overall product sales.
Licenses for non-invasive delivery and stabilization of human growth hormone; GLP-1 analogs; alpha, beta, and gamma interferon; and other drugs are currently available from Aegis with additional patent issuances to be announced shortly.
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. For more information about Aegis, please visit: .
Ralph Barry
Chief Business Officer
Aegis Therapeutics LLC
1-858-618-1400 Ext. 102
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 16.05.2012 - 17:51 Uhr
Sprache: Deutsch
News-ID 147453
Anzahl Zeichen: 0
contact information:
Town:
SAN DIEGO, CA
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 263 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Second Parathyroid Hormone (PTH) Peptide Drug Patent Awarded to Aegis Therapeutics for Compositions Suitable for Metered Nasal Spray, Oral, and Injectable Delivery"
steht unter der journalistisch-redaktionellen Verantwortung von
Aegis Therapeutics LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
